Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) EBITDA Margin (2020 - 2025)

Historic EBITDA Margin for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to 8.67%.

  • Journey Medical's EBITDA Margin rose 111100.0% to 8.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 9.25%, marking a year-over-year increase of 219300.0%. This contributed to the annual value of 24.36% for FY2024, which is 217500.0% down from last year.
  • Per Journey Medical's latest filing, its EBITDA Margin stood at 8.67% for Q3 2025, which was up 111100.0% from 19.16% recorded in Q2 2025.
  • In the past 5 years, Journey Medical's EBITDA Margin registered a high of 49.93% during Q3 2023, and its lowest value of 90.02% during Q2 2021.
  • In the last 5 years, Journey Medical's EBITDA Margin had a median value of 25.3% in 2025 and averaged 31.87%.
  • In the last 5 years, Journey Medical's EBITDA Margin plummeted by -781300bps in 2021 and then soared by 1088300bps in 2023.
  • Over the past 5 years, Journey Medical's EBITDA Margin (Quarter) stood at 51.7% in 2021, then fell by -21bps to 62.6% in 2022, then surged by 78bps to 13.79% in 2023, then soared by 219bps to 16.4% in 2024, then plummeted by -153bps to 8.67% in 2025.
  • Its last three reported values are 8.67% in Q3 2025, 19.16% for Q2 2025, and 25.3% during Q1 2025.